2023
Baseline and Longitudinal Imaging of Hypertrophic Cardiomyopathy in the Era of Emerging Therapeutics
Altibi A, Alani A, Zhao Y, Masri A. Baseline and Longitudinal Imaging of Hypertrophic Cardiomyopathy in the Era of Emerging Therapeutics. Current Cardiology Reports 2023, 25: 583-595. PMID: 37103749, DOI: 10.1007/s11886-023-01883-w.Peer-Reviewed Original ResearchConceptsCardiac myosin inhibitorCardiac magnetic resonance imagingHypertrophic cardiomyopathyCare of patientsClinical trialsPathophysiology of hypertrophic cardiomyopathyCardiac magnetic resonanceNew drug therapiesHypertrophic cardiomyopathy diagnosisActin-myosin cross-bridgesLongitudinal imagingMagnetic resonance imagingMyosin inhibitorTherapeutic optionsAbstract PurposeDrug therapyOral moleculesLongitudinal imaging modalityCardiomyopathyPatientsMonitoring patientsImaging modalitiesResonance imagingInvestigate new drug therapiesSarcomere level
2022
Leveraging Cell-Specific Disease Signatures to Predict New Drug Therapies for Idiopathic Pulmonary Fibrosis
Adams T, Song Q, Justet A, Mcdonough J, DeIuliis G, Yan X, Bar-Joseph Z, Kaminski N. Leveraging Cell-Specific Disease Signatures to Predict New Drug Therapies for Idiopathic Pulmonary Fibrosis. 2022, a2318-a2318. DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2318.Peer-Reviewed Original Research
2021
Update on gout management: what is old and what is new
Afinogenova Y, Danve A, Neogi T. Update on gout management: what is old and what is new. Current Opinion In Rheumatology 2021, 34: 118-124. PMID: 34907116, PMCID: PMC8799507, DOI: 10.1097/bor.0000000000000861.Peer-Reviewed Original ResearchConceptsUrate-lowering therapyRisk factorsAdjunctive management strategiesUrate-lowering efficacyChronic kidney diseaseUse of allopurinolAllopurinol hypersensitivity syndromeManagement of hyperuricemiaCrystal-Associated Disease NetworkPopulation attributable riskEvidence-based recommendationsComprehensive evidence-based recommendationsNew drug therapiesGout guidelinesCause mortalityHypersensitivity syndromeCardiovascular riskGout flaresGout managementKidney diseaseDrug therapyFlare managementAttributable riskDietary factorsSerum urate
2014
The consequences of refractory epilepsy and its treatment
Laxer KD, Trinka E, Hirsch LJ, Cendes F, Langfitt J, Delanty N, Resnick T, Benbadis SR. The consequences of refractory epilepsy and its treatment. Epilepsy & Behavior 2014, 37: 59-70. PMID: 24980390, DOI: 10.1016/j.yebeh.2014.05.031.Peer-Reviewed Original ResearchConceptsRefractory epilepsyPractical clinical recommendationsNew drug therapiesPersistent seizuresOngoing seizuresSurgical treatmentAntiepileptic drugsUncontrolled seizuresDrug therapyEpilepsy expertsEpileptogenic processPsychosocial burdenClinical recommendationsNeuropsychiatric impairmentNervous systemEpilepsyProgressive epilepsySeizuresDiagnostic proceduresVocational consequencesAdverse effectsPatientsRiskTreatmentBurden
2012
Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons
Dietrich MO, Horvath TL. Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. Nature Reviews Drug Discovery 2012, 11: 675-691. PMID: 22858652, DOI: 10.1038/nrd3739.Peer-Reviewed Original ResearchConceptsNPY/AgRP neuronsNegative energy balanceSevere side effectsAgRP neuronsPOMC neuronsPositive energy balanceChronic disordersPeripheral tissuesReactive oxygen speciesSide effectsLong-term positive energy balanceCalorie restrictionAnti-obesity drug developmentBehavioral interventionsIntense behavioral interventionsPro-opiomelanocortin (POMC) neuronsChronic metabolic disorderLong-term treatmentWhite adipose tissueAlternative therapeutic approachAnti-obesity therapiesPromotion of satietyNew drug therapiesPopulations of neuronsHigher brain functions
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply